UBS Group
ADAP

UBS Group’s Adaptimmune Therapeutics ADAP Stock Holding History

UBS Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,667,358
Closed -$867K – 10439
2025
Q3 		$867K Buy
6,667,358
+6,604,400
+10,490% +$906K ﹤0.01% 5687
2025
Q2 		$15.1K Sell
62,958
-949,782
-94% -$253K ﹤0.01% 8627
2025
Q1 		$200K Buy
1,012,740
+870,996
+614% +$451K ﹤0.01% 6563
2024
Q4 		$76.4K Buy
141,744
+139,927
+7,701% +$102K ﹤0.01% 7040
2024
Q3 		$1.73K Hold
1,817
– – ﹤0.01% 8565
2024
Q2 		$1.77K Sell
1,817
-194,879
-99% -$214K ﹤0.01% 8496
2024
Q1 		$311K Buy
196,696
+172,003
+697% +$208K ﹤0.01% 5540
2023
Q4 		$19.6K Sell
24,693
-3,641
-13% -$2.05K ﹤0.01% 7116
2023
Q3 		$22.1K Sell
28,334
-2,646
-9% -$2.22K ﹤0.01% 6755
2023
Q2 		$28.7K Buy
30,980
+4,230
+16% +$5.04K ﹤0.01% 6735
2023
Q1 		$29.2K Buy
26,750
+3,125
+13% +$4.84K ﹤0.01% 6819
2022
Q4 		$34.5K Buy
23,625
+21,641
+1,091% +$35K ﹤0.01% 7097
2022
Q3 		$2K Sell
1,984
-2,720
-58% -$5K ﹤0.01% 9687
2022
Q2 		$8K Sell
4,704
-788
-14% -$1.35K ﹤0.01% 8276
2022
Q1 		$12K Sell
5,492
-11,080
-67% -$29.9K ﹤0.01% 8148
2021
Q4 		$61K Buy
16,572
+1,067
+7% +$4.86K ﹤0.01% 6734
2021
Q3 		$80K Buy
15,505
+1,593
+11% +$7.15K ﹤0.01% 5982
2021
Q2 		$60K Sell
13,912
-174,172
-93% -$845K ﹤0.01% 6264
2021
Q1 		$998K Buy
188,084
+6,502
+4% +$37.2K ﹤0.01% 4249
2020
Q4 		$978K Buy
181,582
+56,249
+45% +$306K ﹤0.01% 4047
2020
Q3 		$1M Buy
125,333
+125,263
+178,947% +$1.1M ﹤0.01% 3638
2020
Q2 		$1K Sell
70
-5,015
-99% -$31.5K ﹤0.01% 7729
2020
Q1 		$14K Sell
5,085
-1,142
-18% -$3.79K ﹤0.01% 6710
2019
Q4 		$7K Buy
6,227
+6,157
+8,796% +$6.57K ﹤0.01% 7430
2019
Q3 		$0 Sell
70
-8,030
-99% -$18.8K ﹤0.01% 7948
2019
Q2 		$32K Buy
8,100
+2,630
+48% +$10.7K ﹤0.01% 6278
2019
Q1 		$24K Sell
5,470
-2,100
-28% -$9.78K ﹤0.01% 6135
2018
Q4 		$44K Sell
7,570
-110,258
-94% -$814K ﹤0.01% 6202
2018
Q3 		$1.6M Buy
117,828
+106,170
+911% +$1.11M ﹤0.01% 3416
2018
Q2 		$138K Buy
11,658
+8,228
+240% +$103K ﹤0.01% 5213
2018
Q1 		$38K Sell
3,430
-2,467
-42% -$21.6K ﹤0.01% 5912
2017
Q4 		$39K Buy
5,897
+4,397
+293% +$34K ﹤0.01% 6038
2017
Q3 		$12K Sell
1,500
-500
-25% -$3.12K ﹤0.01% 6764
2017
Q2 		$9K Buy
2,000
+1,228
+159% +$6.42K ﹤0.01% 6827
2017
Q1 		$4K Sell
772
-2
-0.3% -$9 ﹤0.01% 7053
2016
Q4 		$3K Sell
774
-2,436
-76% -$11.7K ﹤0.01% 7392
2016
Q3 		$23K Buy
+3,210
New +$24.5K ﹤0.01% 6183
2016
Q1 		– Sell
-5,164
Closed -$62K – 7578
2015
Q4 		$62K Buy
5,164
+3,303
+177% +$32.3K ﹤0.01% 5626
2015
Q3 		$22K Sell
1,861
-294
-14% -$4.15K ﹤0.01% 6603
2015
Q2 		$40K Buy
+2,155
New +$37K ﹤0.01% 6194

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group's ADAP Position: Q4 2025 in Review

UBS Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 6,667,358 shares — an estimated $867K sold.

UBS Group first reported a position in ADAP in Q2 2015 and held it in 40 quarters. The position peaked at $1.6M in Q3 2018. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • UBS Group reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • UBS Group sold 6,667,358 Adaptimmune Therapeutics shares in Q4 2025, an estimated $867K.
  • UBS Group first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 40 quarters.
  • UBS Group's Adaptimmune Therapeutics position peaked at $1.6M in Q3 2018.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.